Sotatercept significantly reduces pulmonary vascular resistance in patients with CpcPH–HFpEF compared with placebo, according to a trial.
Higher pulmonary resistance was associated with worse outcomes in pulmonary hypertension, while SGLT2 inhibitors may improve ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results